Rybelsus (semaglutide) 3mg is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus. Semaglutide works by stimulating insulin secretion and inhibiting glucagon release in a glucose-dependent manner, leading to improved glycemic control. Clinical studies have shown that Rybelsus can significantly reduce HbA1c levels, promote weight loss, and lower the risk of cardiovascular events in patients with diabetes. It is administered orally once daily to enhance patient adherence and convenience.